Photo: Olivev Radin/Pacific Press/LightRocket/ Getty ImagesRegeneron has had another success in recent weeks. After the Ebola drug was approved, he received ad hoc approval to use the drug against COVID-19
The American Food and Drug Administration (FDA, Food and Drug Administration) has approved Regeneron’s COVID-19 antibody therapy on an ad hoc basis, CNBC informs. Its experimental version was used a few weeks ago when the coronavirus was banned by President Donald Trump.
The Regeneron Pharmaceuticals biotech company, based in Tarrytown, New York, has applied for approval for the ad hoc use of its proprietary drug REGN-COV2 when preclinical studies on primates have shown that the specificity limits virus multiplication and associated lung damage.